Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.

Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, Martinez-Turrillas R, Torella L, Vales A, Olagüe C, Vilas-Zornoza A, Castro-Labrador L, Lara-Astiaso D, Prosper F, Salido E, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR.

Nat Commun. 2018 Dec 21;9(1):5454. doi: 10.1038/s41467-018-07827-1.

2.

Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction" [J Hepatol 67 (2017) 669-679].

Suárez-Amarán L, Usai C, Di Scala M, Godoy C, Ni Y, Hommel M, Palomo L, Segura V, Olagüe C, Vales A, Ruiz-Ripa A, Buti M, Salido E, Prieto J, Urban S, Rodríguez-Frias F, Aldabe R, González-Aseguinolaza G.

J Hepatol. 2018 Jul;69(1):262-264. doi: 10.1016/j.jhep.2018.04.003. No abstract available.

PMID:
29776712
3.

A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.

Suárez-Amarán L, Usai C, Di Scala M, Godoy C, Ni Y, Hommel M, Palomo L, Segura V, Olagüe C, Vales A, Ruiz-Ripa A, Buti M, Salido E, Prieto J, Urban S, Rodríguez-Frias F, Aldabe R, González-Aseguinolaza G.

J Hepatol. 2017 Oct;67(4):669-679. doi: 10.1016/j.jhep.2017.05.010. Epub 2017 May 18. Erratum in: J Hepatol. 2018 May 15;:.

PMID:
28527664
4.

Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice.

Di Scala M, Otano I, Gil-Fariña I, Vanrell L, Hommel M, Olagüe C, Vales A, Galarraga M, Guembe L, Ortiz de Solorzano C, Ghosh I, Maini MK, Prieto J, González-Aseguinolaza G.

J Virol. 2016 Sep 12;90(19):8563-74. doi: 10.1128/JVI.01030-16. Print 2016 Oct 1.

5.

Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure.

Di Scala M, Gil-Fariña I, Olagüe C, Vales A, Sobrevals L, Fortes P, Corbacho D, González-Aseguinolaza G.

Oncotarget. 2016 Aug 2;7(31):49008-49026. doi: 10.18632/oncotarget.10264.

6.

A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response.

Nistal-Villán E, Rodríguez-García E, Di Scala M, Ferrero-Laborda R, Olagüe C, Vales Á, Carte-Abad B, Crespo I, García-Sastre A, Prieto J, Larrea E, González-Aseguinolaza G.

J Innate Immun. 2015;7(5):466-81. doi: 10.1159/000375262. Epub 2015 May 5.

7.

Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice.

Di Scala M, Gil-Fariña I, Vanrell L, Sánchez-Bayona R, Alignani D, Olagüe C, Vales A, Berraondo P, Prieto J, González-Aseguinolaza G.

Haematologica. 2015 Aug;100(8):1014-22. doi: 10.3324/haematol.2014.115410. Epub 2015 Feb 24.

8.

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.

Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno U, Bunuales M, Olagüe C, Razquin N, Van Rooijen N, Enguita M, Hernandez-Alcoceba R.

Liver Int. 2015 Apr;35(4):1274-89. doi: 10.1111/liv.12571. Epub 2014 May 10.

PMID:
24754307
9.

Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.

Pañeda A, Lopez-Franco E, Kaeppel C, Unzu C, Gil-Royo AG, D'Avola D, Beattie SG, Olagüe C, Ferrero R, Sampedro A, Mauleon I, Hermening S, Salmon F, Benito A, Gavira JJ, Cornet ME, del Mar Municio M, von Kalle C, Petry H, Prieto J, Schmidt M, Fontanellas A, González-Aseguinolaza G.

Hum Gene Ther. 2013 Dec;24(12):1007-17. doi: 10.1089/hum.2013.166.

PMID:
24070415
10.

IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression.

Gil-Fariña I, Di Scala M, Vanrell L, Olagüe C, Vales A, High KA, Prieto J, Mingozzi F, Gonzalez-Aseguinolaza G.

PLoS One. 2013 Jul 2;8(7):e67748. doi: 10.1371/journal.pone.0067748. Print 2013.

11.

Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B.

Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, Olagüe C, Vales A, Riezu JI, Larrea E, Borras F, Benito A, Hernandez-Alcoceba R, Menne S, Prieto J, González-Aseguinolaza G.

Hepatology. 2012 Aug;56(2):474-83. doi: 10.1002/hep.25667. Epub 2012 Jul 2.

PMID:
22334260
12.

A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.

Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, Qian C, Benito A, Larrache J, Olagüe C, Boan J, Peñuelas I, Sádaba B, Prieto J.

Cancer Gene Ther. 2010 Dec;17(12):837-43. doi: 10.1038/cgt.2010.40. Epub 2010 Aug 6.

PMID:
20689572
13.

Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice.

Ochoa-Callejero L, Otano I, Vales A, Olagüe C, Sarobe P, Lasarte JJ, Prieto J, Menne S, González-Aseguinolaza G.

Vaccine. 2010 Jul 19;28(32):5323-31.

PMID:
20665977
14.

Characterization of high-capacity adenovirus production by the quantitative real-time polymerase chain reaction: a comparative study of different titration methods.

Crettaz J, Olague C, Vales A, Aurrekoetxea I, Berraondo P, Otano I, Kochanek S, Prieto J, González-Aseguinolaza G.

J Gene Med. 2008 Oct;10(10):1092-101. doi: 10.1002/jgm.1236.

PMID:
18642400
15.

Woodchuck dendritic cells generated from peripheral blood mononuclear cells and transduced with recombinant human adenovirus serotype 5 induce antigen-specific cellular immune responses.

Ochoa-Callejero L, Berraondo P, Crettaz J, Olagüe C, Vales A, Ruiz J, Prieto J, Tennant BC, Menne S, González-Aseguinolaza G.

J Med Virol. 2007 May;79(5):522-9.

PMID:
17385694
16.

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I.

J Clin Oncol. 2005 Feb 10;23(5):999-1010. Epub 2004 Dec 14.

17.

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olagüe C, Sola J, Sádaba B, Lacasa C, Melero I, Qian C, Prieto J.

J Clin Oncol. 2004 Apr 15;22(8):1389-97.

PMID:
15084613

Supplemental Content

Loading ...
Support Center